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ABSTRACT 
THE ROLE OF SRC IN NSCLC CELL AND LUNG FIBROBLAST MIGRATION 
ON 3D CELL-DERIVED MATRIX 
Austin M. Krueger 
April 13, 2021 
Lung cancer is responsible for the most cancer deaths between males and 
females, with a 6% five-year survival rate. Cancer metastasis is one of the 
leading causes of lung cancer lethality. Our lab has developed a method to 
culture cells on cell-derived matrix (CDM) and study cell-ECM interactions. This 
study utilized multiple cell migration methods to investigate the migration of 
NSCLC cells and IMR90 lung fibroblasts, both together and independently, on 2D 
plastic and 3D CDM. Our results showed that inhibiting Src, a significant 
influencer of cell migration and member of integrin activation, blocked cancer cell 
migration on 2D and 3D CDM, regardless of interactions with fibroblasts or not. 
However, when IMR90 lung fibroblasts were treated with a Src inhibitor, 
migration decreased on 2D but not on 3D. These results suggest that cancer 
cells migrate in a Src-dependent manner on 3D CDM, but IMR90 lung fibroblasts 
do not. 
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Lung cancer is the leading cause of cancer deaths among males and 
females, accounting for the second most common type in both sexes in the United 
States [1]. Not only does lung cancer account for the most deaths, but it is also 
more fatal than colon, breast, and prostate combined [1]. There are two 
classifications of lung cancer: small cell and non-small cell [1, 2]. Small cell lung 
cancer accounts for an estimated 15% of lung cancer cases [2]. However, small 
cell lung cancer is more deadly than non-small cell lung cancer, with a 6% 5-year 
survival rate [2]. Non-small cell lung cancer (NSCLC) is further classified into three 
groups: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. 
Adenocarcinoma is not only the most common cancer type worldwide but also the 
most common cancer type of NSCLC, accounting for more than 40% of incidences. 
It is evident that lung cancer poses a significant hurdle in cancer research today, 
but what is causing it? 
Lung Cancer Metastasis 
The National Cancer Institute defines metastasis as "the spread of cancer 
cells from the place where they first formed to another part of the body." The 
metastatic spread of cancer accounts for approximately 90% of cancer deaths [3]. 
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Traditionally, a lung cancer patient may not observe significant symptoms until the 
disease has reached a later stage involving metastasis. If a patient is first 
diagnosed with lung cancer that metastasized to distant regions (regions other 
than the lung and tissues surrounding the lung), their chance to survive more than 
5 years is 6% [1]. It is evident that most lung cancer deaths are due to metastasis 
and detecting the disease too late. Although several lung cancer prevention 
methods (screening, healthy diet/lifestyle, and avoiding smoking), there is still a 
considerable need to treat those with metastatic lung cancer. 
Cancer metastasis can be divided into four separate stages: invasion and 
intravasation, circulation, extravasation, and metastatic colonization [3]. The first 
step in cancer metastasis is the cancer cells gaining enough mutations and tumor 
microenvironment (TME) cues to invade through the tissue's basement membrane 
[3]. Once they have invaded through the basement membrane, cancer cells can 
enter the patient's blood circulation. In animal models, approximately 0.01% of 
cancer cells survive in the host's blood circulation [4]. Because cancer cells are 
genetically unstable, the small percentage of cancer cells that remain in the host's 
circulation blood could extravasate. Following extravasation, the cancer cell may 
form a metastatic colony in another part of the body. So, how does one target 
cancer cell metastasis? 
Tumor Microenvironment 
The TME is an emerging topic in metastatic cancer research. Composed of 
numerous cell types, the TME plays a vital role in cancer cell survival, proliferation, 
and metastasis [5]. The primary cell types of the TME are cancer cells, epithelial 
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cells, endothelial cells, fibroblasts, cancer-associated fibroblasts, and a plethora of 
immune cells [6]. Some non-cell components are the extracellular matrix (ECM), 
cytokines (growth factors, chemokines, etc.), and secreted proteins [6]. Targeting 
cancer metastasis has proven to be difficult. One possible reason is that many in 
vitro studies do not take the ECM into account. To investigate the interaction of 
NSCLC cells and the ECM, the entire TME must be considered. 
Of the cellular components of the TME, fibroblasts perform critical functions 
in the interaction between cancer cells and the ECM. The major ECM secreting 
cell type in the body is fibroblasts [6]. Additionally, fibroblasts are responsible for 
secreting growth factors and other proteins involved in ECM remodeling [6]. An 
exciting topic in cancer research is investigating cancer-associated fibroblasts 
(CAFs). CAFs are commonly derived from tissue-resident fibroblasts and induced 
by components of the TME. Numerous studies show the different effects CAFs 
have on the TME as opposed to non-CAFs [7]. Among those differences are 
growth factor and cytokine secretions, as well as ECM remodeling [8]. Together, 
the impact of fibroblasts on the TME is vital in the ECM-cancer cell interplay. 
The Extracellular Matrix Environment 
The ECM contains many different compartments connecting the cell with 
the surrounding environment and impacting the cell on many different levels. The 
major structural components of the ECM are collagen, proteoglycans, laminin, and 
fibronectin [9]. Collagens are the most abundant proteins in the human body, 
comprising nearly 30% of tissue mass, including 28 different subtypes [10]. 
Collagens lay the foundation for the architecture of the ECM. Proteoglycans are 
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composed of several subtypes. Perlecan, hyalecan, and small leucine-rich 
proteoglycan (SLRP) are the main proteoglycans that make up the ECM [9]. They 
play roles in collagen-fibronectin and collagen-collagen connections acting as the 
"glue" to hold the ECM together [11]. Laminins are made up of alpha, gamma, and 
delta chains comprising 16 different combinations. They are responsible for 
connecting the cell to the ECM [9]. Lastly, fibronectin is a multi-domain protein that 
interacts with the previous structural components discussed. Through these 
interactions, fibronectin provides connecting points for the cell and ECM. Each 
structural element of the ECM plays a unique role in the cancer cell-ECM 
interaction. 
Embedded in the ECM are multiple types of ligands, including growth 
factors, chemokines, and other cytokines proteins, as well as proteases 
responsible for degrading the ECM [12]. Essential growth factors are tumor growth 
factor-ß, interleukins, insulin-like growth factors, and epithelial growth factor [13]. 
Matrix metalloproteases play a critical role in ECM degradation, providing space 
for the cell to move through [14]. Each part of the ECM environment is involved in 
the ECM-cell interaction. 
Aside from the external compartments, there is a copious number of 
components integrated into the cell membrane. Of these, integrins are one of the 
most critical transmembrane proteins involved in ECM-cell interactions. They 
contain an alpha and beta subunit, composing 24 known heterodimers with 
individual functions [15]. Binding to the ECM through collagen, laminin, and 
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fibronectin, integrins provide a crucial cell connection to the ECM [16]. Their 
functions in cell invasion, adhesion, and migration are well documented. 
AlphaV-Beta3 and Alpha5-Beta1 integrins, specifically, lead to focal 
adhesion kinase (FAK), Src family kinase (SFK) signaling activation, and eventual 
ERK, JUN, and Rac signaling activation [17]. When the integrins interact with the 
structural components and ligands of the ECM, the intracellular beta domain is 
activated by MRL proteins (MIG-10, RIAM, and Lamellipodin) [18] and recruits talin 
to promote actin polymerization and integrin clustering [16]. Integrin clustering 
ensures FAK and SFK activation. FAK/SFK and their downstream activation play 
one of the most critical roles in cell adhesion and movement. 
Epithelial to Mesenchymal Transition 
The Epithelial to Mesenchymal Transition (EMT) describes the 
transformation of epithelial-like cells to mesenchymal state [19]. An "epithelial-like" 
cell's rectangular shape will transition into a spindle-like, mesenchymal shape [20]. 
The transformation induces the cell to behave more stem-like, increasing its 
invasive and migratory phenotypes [19]. EMT contains a highly complex network 
of signaling to induce the mesenchymal states. The primary EMT inducers are 
TGF-beta, Wnt, Notch, hypoxia, PIK3, JAK/STAT, and integrin activation [21]. 
These pathways lead to the activation of critical EMT transcription factors: Snail 1, 
Slug, ZEB1/2, and Twist [21]. The transcription factors suppress the expression of 
crucial epithelial transition signalings, such as E-cadherin, occludins, claudins, and 
cytokeratins. N-cadherin, Vimentin, fibronectin, and MMPs are upregulated by the 
EMT transcription factors [19]. Not only do integrin-mediated FAK/SFK signaling 
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and MMP activity play a critical role in cell-ECM interaction and remodeling, but 
they also are integral members of EMT.  
 The interaction between the cell and the extracellular matrix plays a vital 
role in cancer cell metastasis through external cues, such as ligand binding and 
integrin activation. Ligands embedded in the ECM and mutations acquired by 
cancer cells induce EMT through receptor-mediated activation. For example, TGF-
beta, which is secreted by multiple cell types, induces EMT through the activation 
of SMAD2/3 and RAS/MAPK/ERK induction of EMT transcription factors [19]. 
Additionally, integrin activation induces FAK/SFK signaling to activate RAS, PI3K, 
STAT signaling, and EMT transcription factors [19]. Lastly, SNAIL1 and ZEB2 
moderated the activation of MMPs responsible for ECM degradation [19]. How can 
one phenotypically show that alterations of these interactions influence cancer cell 
phenotype? 
Cell Migration and Invasion 
 The ECM plays a crucial role in cell migration and invasion through 
alterations in signaling cascades related to EMT. Considering cancer metastasis 
steps, studying the invasion and migration of cancer cells in vitro can help 
researchers target cancer cell migration mechanisms from the primary tumor site. 
Four in vitro approaches to studying cancer cell migration are spheroid, scratch 
would, individual cell tracking, and trans-well assays: 
1. A spheroid assay can be performed by culturing cancer cells in a non-
adherent, round bottom 96-well plate long enough for the cells to form a 
spherical structure, the "spheroid" [22]. The spheroid is transferred to 
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another plate, and the migration of cells from the spheroid can be monitored 
over time. This assay is a measure of collective cell migration. Using 
ImageJ, a software provided by the NIH, the migration of cells can be 
quantified by defining the area of which the cells have migrated away from 
the core of the spheroid. 
2. A scratch wound assay can be performed by creating a wound in a confluent
cancer cell monolayer [23]. Once the wound is made, the collective 
migration of cells to close the wound can be monitored over time. Using 
ImageJ, a software provided by the NIH, the migration of cells can be 
quantified by defining the area of which the cells have migrated into the 
wound. This may be referred to as the wound closure. 
3. One may also monitor individual cell migration by individually tracking
cancer cells' velocity and directionality over time [24]. This may be done by 
adding a low concentration, single-cell suspension, to a cell culture plate. 
The cells are monitored over time using live-cell imaging and utilizing 
available cell tracking softwares. 
4. A trans-well assay is performed by culturing cancer cells in nutrient-free
media on top of a Boyden chamber. The Boyden chamber contains small 
pores wide enough for single cells to fit through [25]. On the other side of 
the pore is media containing nutrients and other factors to attract the cancer 
cells [25]. One can then quantify the number of cells that migrated through 
the pores over time by quantifying the number of cells attached to the 
bottom of the cell culture plate. 
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Together, these four assays allow researchers to study cancer cell migration from 
many different angles. 
A critical step in cancer metastasis is cancer cells breaking through the 
basement membrane and out of the primary tumor site to other sites in the body. 
Invasion assays are very similar to migration assays except for one added 
component: Matrigel. Matrigel is a gel-like substance at room temperature that can 
act as a basement membrane and is comparable to embryonic basement 
membranes [26]. In-depth proteomic analysis shows the key components of 
Matrigel are laminin-1, collagen IV, entactin, and heparan sulfate proteoglycan, 
which provide both structural support and comparable signal transduction to the 
embryonic basement membrane/ECM [27]. With Matrigel, researchers can modify 
migration assays into invasion assays: 
1. Adding Matrigel to the non-adherent well containing the spheroid
encapsulates the spheroid with the gel-like substance [22]. Cells then 
invade into the gel surrounding the spheroid as well as away from the 
spheroid itself. Using ImageJ, a software provided by the NIH, the migration 
of cells can be quantified by defining the area of which the cells have 
migrated away from the core of the spheroid. 
2. In a scratch wound assay, the addition of a thin monolayer of Matrigel to
the top of the cells overlays the wound made. This allows the cells to invade 
into the wound [28]. Using ImageJ, a software provided by the NIH, the 
migration of cells can be quantified by defining the area of which the cells 
have migrated into the wound. 
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3. By creating a 1:1 ratio of low concentrated, single-cell suspension and
Matrigel, one can add the mixture to a cell culture plate. Because the cells 
are encapsulated in Matrigel, cells are forced to invade through the gel-like 
substance [24]. The cells are monitored over time using live-cell imaging 
and utilizing available cell tracking softwares. 
4. Adding a layer of Matrigel to the Boyden chamber pores would force the
cells to invade through the Matrigel to reach the nutrient-filled media below 
[29]. One can then quantify the number of cells that migrated through the 
pores over time by quantifying the number of cells attached to the bottom 
of the cell culture plate. 
Using these techniques, researchers can study cancer cell invasion in vitro. 
The World Health Organization reported approximately 10 million people 
die from cancer each year. As one of the leading causes of death worldwide, 
cancer research is crucial in finding better treatments for cancer patients. Because 
cancer metastasis is responsible for a worse 5-year survival rate, investigating 
cancer cell migration and invasion may provide helpful information to design drugs 
to target cancer metastasis. There are multiple assays to study cancer cell 
migration and invasion, each with its own positive and negative characteristics. 
Choosing which assay to use will depend on a researcher's available technology 
and time. 
Cell-Derived Matrices 
Knowing that the ECM plays a pivotal role in cancer cell migration and 
invasion, how do researchers apply this concept to the previously discussed 
10 
migration and invasion assays? Utilizing fibroblasts' ability to produce a surplus of 
extracellular matrix, one can culture fibroblasts long enough to deposit a layer of 
ECM on a cell culture plate. Once the fibroblasts decellularized from the plate, a 
layer of ECM is left behind. Researchers can then seed cells on top of the ECM 
layer and study the cell's interaction with the ECM [30].  
The most apparent difference between cells cultured on 3D CDM and 2D 
plastic is the cell phenotype. To perform various migration and invasions assays 
using 3D CDM, one would perform the assay the same way except that the cells 
are cultured on 3D CDM. Cells naturally shaped like a cube in standard 2D culture 
methods appear more elongated and spindle-like in a 3D CDM environment [28]. 
With this phenotype, researchers studied the signaling differences in cells cultured 
in a 3D CDM system. Remarkably, the differences were incredibly obtuse. EMT 
markers were increased in cells cultured on 3D CDM, and the proliferation, 
migration, and invasion of cancer cells were significantly different [30]. Specifically, 
epithelial markers were decreased, and mesenchymal markers were increased in 
cells cultured on 3D CDM [30]. FAK/SFK signaling is also affected. Phenotypically, 
proliferation is slightly decreased while migration and invasion are increased [30]. 
Culturing cells on 2D plastic as opposed to 3D CDM yields different phenotypes 
and cancer cell signaling. 
Cell-derived matrices (CDMs) impact cells in many ways, and the 
technique is well documented and highly reproducible [28] [30] [31]. It is 
postulated that culturing cells on ECM is a more physiologically relevant model 
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for cancer research in vitro. Using 3D CDM culture techniques may yield more 
consistent in vitro results. 
ECM Remodeling 
Velocity and displacement increased significantly in NSCLC cells cultured 
on 3D CDM [30]. An important distinction between 3D CDM and 2D plastic is the 
physical appearance. Expectedly, 2D plastic looks flat and appears smooth. 3D 
CDM seems more rigid and gelatinous. Using light microscopy, one can see the 
collagen fibers of the ECM are aligned in a web-like network. As a whole, the 
CDM may seem unorganized; however, the CDM's rigidity is what provides 
directionality to the cells. Cell-derived ECM provides a road network for cells 
cultured on CDM. Cancer cells react to the framework the CDM provides. 
Fibroblasts are the central regulators of the tumor ECM environment [32]. 
They are responsible for secreting soluble actors, ECM remodeling, metabolic 
effects, and immune crosstalk and secrete many different soluble secretory 
factors, such as VEG-F and TGF-Beta [32]. They remodel the ECM through 
matrix crosslinking, proteolysis, and matrix production [32]. Metabolic effects 
include lactate shuffling (providing lactate to cancer cells dependent on such for 
energy) and amino acid shuffling [32]. Lastly, fibroblasts interact with surrounding 
immune cells through TGF-Beta and IL-6 activation and CCL2 production. The 
interaction between cancer cells and fibroblasts is synergistic, meaning 
fibroblasts can prime cancer cells for invasion/migration, and cancer cells can 
induce an activated phenotype of fibroblasts. 
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It is thought that there are three resting states of fibroblasts: resting, 
normal-activated, and fibrosis/cancer-associated [33]. Fibroblasts are typically 
found in a resting form where surrounding stimuli can activate them to normal-
activated fibroblasts. In their resting state, fibroblasts are spindle-shaped, do not 
migrate, produce ECM, or secrete soluble factors [33]. Normal-activated 
fibroblasts are identified primarily through alpha-SMA and vimentin expression 
[33]. This transition is reversible through genetic reprogramming and induction of 
apoptosis. Normal-activated fibroblasts play a considerable role in wound healing 
and fibrosis. From the normal activated state, fibroblasts can transition into 
fibrosis- or cancer-associated fibroblasts through epigenetic regulation. One key 
identifiable marker is fibroblast activation protein expression. The critical 
difference between the two states is that cancer-associated fibroblasts proliferate 
more, secrete more growth factors, and do not produce as much ECM [33]. Once 
fibroblasts are in this state, they cannot revert to normal-activated fibroblasts. 
It is apparent that taking into account multiple members of the TME is 
increasingly vital in studying cancer cell migration and invasion. Our study aimed 
to investigate the interaction between cancer cells, fibroblasts, and the ECM 
independently and co-dependently. Our results suggest that NSCLC cells and 
fibroblasts migrate through different migration mechanisms on 3D cell-derived 
matrix, where they migrate through similar mechanisms on 2D. This information 
is critical in elucidating the methods by which the TME impacts cancer cell 
migration. 
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MATERIALS AND METHODS 
Cell culture 
Human normal fetal lung fibroblast cell lines WI38, IMR90, and CCL-201 were 
purchased from American Type Culture Collection (ATCC) and maintained in 
Minimum Essential Medium Alpha modification (MEM-α) supplemented with L-
Gln, ribo- and deoxyribonucleosides (Fisher),10% fetal bovine serum (Invitrogen) 
and 1% antibiotic/antimycotic (Sigma). Human mesenchymal cell lines (WI38 and 
IMR90) were performed with early passage cells (p < 8) in the same culturing 
medium, MEMα, described previously. A549, H2009, and H2030 human 
adenocarcinoma cells were purchased from ATCC and were cultured in RPMI 
medium supplemented with 10% FBS and 1% antibiotic. All cell lines were 
maintained at 37ºC and 5% CO2, unless otherwise stated. 
Extracellular Matrix Preparation 
Extracellular matrix preparation was performed as previously described [30]. 
Briefly, IMR90, WI38, or CCL-201 lung fibroblasts were plated at confluence in 
matrix
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growth medium (MEM-α, 10% FBS, 1% antibiotic). On the second, fourth, and 
sixth days, medium was supplemented with 50 µg/mL L-Ascorbic acid (Sigma) to 
promote matrix deposition. On the eighth day, wells were washed with phosphate 
buffered saline (PBS), and cells were lysed with a detergent (20mM NH4OH, 
0.05% Triton-X-100) for 1-3 minute incubation at 37º C until complete cell lysis 
was observed. The resulting cell-derived matrices were gently washed three 
times with PBS and then incubated with Dnase1 (10 U/mL) for 30-60 minutes to 
remove residual DNA. The matrices were then washed twice in PBS and either 
used immediately or stored at 4ºC in PBS supplemented with 1% antibiotic for up 
to 4 months. 
Microscopy 
Live-cell time-lapse phase and fluorescence microscopy were performed using a 
Keyence All-in-One Fluorescence Microscope (BZ-X series). 
Scratch Wound Migration Assay 
Lung cancer cells were plated at confluence and serum-starved overnight 
following attachment. A micropipette tip was used to create a scratch in the cell 
monolayer, and pictures were captured at the indicated time points. 3D invasion 
assays were plated using a WI38 derived matrix that had not been supplemented 
with ascorbic acid during the growth. Ascorbic acid supplementation or use of 
IMR90 fibroblast matrices results in a matrix that was too thick to scratch reliably. 
Images were captured at the indicated timepoints. Results were quantified using 
the area measurement of imageJ, comparing the wound closure at the time of 
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the image to the initial wound. Averages of at least three images were captured 
for each time point, and at least two replicates were used for each experiment. 
Spheroid Preparation 
Lung cancer cells were culture under normal conditions on a Corning ultralow 
attachment 96 well plate (Sigma) at 1x104 cells per well for 4 days to allow small, 
rounded spheroids. Spheroids were observed under microscopy and transferred 
to matrix plates with a micropipette for further migration studies. 
Western Blot 
Cells and tissue samples were harvested in CHAPS lysis buffer (1% CHAPS 
detergent, 150mM NaCl, 50mM Tris pH7, 5mM EDTA) supplemented with 
complete protease inhibitor and PhosSTOP phosphatase inhibitor cocktail tablets 
(Sigma-Aldrich, St. Louis, MO). Total protein (40µg) was heated at 95ºC for 5 
minutes and separated by 4-12% SDS-polyacrylamide gel. Blots were transferred 
to PVDF membranes for 120 minutes at a constant voltage of 100 V in 4ºC. 
Membranes were blocked in 5% milk (w/v) in Tris-buffered saline Tween-20 
(TBS-T) at 24ºC for 1 hour. The membranes were incubated with the primary 
antibody in 5% milk TBS-T overnight at 4ºC. A list of antibodies used for analysis 
is presented in the supplementary material. 
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Table 1. Antibodies. 
Antibody Host Catalog Distributor 
Src Rabbit #2108 Cell Signaling Technologies 
P-Src Family (Tyr416) Rabbit #2101 Cell Signaling Technologies 
FAK (D2R2E) Rabbit #13009 Cell Signaling Technologies 
P-FAK (Tyr397) (D20B1) Rabbit #8556 Cell Signaling Technologies 
GAPDH (D16H11)  Rabbit #5174 Cell Signaling Technologies 
Rabbit IgG HRP Goat #7074 Cell Signaling Technologies 
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Statistics 
Student's t-tests were used for comparisons between two groups. A one-way 
ANOVA with Tukey's test for multiple comparisons was used to determine 
statistical significance for multiple groups, unless otherwise stated. Statistical 
significance was considered for P-value < 0.05. 
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RESULTS 
Non-small cell lung cancer cell migration increases on 3D cell-derived 
matrix.  
We have previously shown that cancer cell signaling and proliferation change on 
the 3D cell-derived matrix [30]. To investigate how culturing cells on 3D cell-
derived matrix influences cell migration, we examined spheroid spreading on 2D 
plastic and 3D IMR90-derived matrix. Hop62 non-small cell lung cancer (NSCLC) 
cell spheroids were cultured on 2D plastic and 3D IMR90-derived matrix for 48 
hours (Figure 1a). The migrational area of the spheroids was measured and 
quantified via ImageJ. Hop62 spheroids cultured on 3D migrated significantly 
more than the spheroids cultured on 2D (Figure 1b).
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Figure 1. Collective cell migration increases in Hop62 lung cancer cells on 
3D. 
Hop62 spheroids were grown for four days and transferred to 2D plastic, and 3D 
IMR90 derived ECM. A) Schematic of Spheroid Migration Assay. B) Images were 
captured at 0 and 48 hours after initial plating. C) Quantification of total migrated 
area relative to the area of the spheroid. Statistical analysis performed by 
unpaired T-test was performed, ** p<0.01; Data presented as mean ±S.E.M. 
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H2030 NSCLC cell spheroids were cultured on 2D plastic and 3D IMR90-derived 
matrix for 48 hours (Figure 2a). The migrational area of the spheroids was 
measured and quantified via ImageJ. H2030 spheroids cultured on 3D migrated 
significantly more than the spheroids cultured on 2D (Figure 2b). 
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Figure 2. Collective cell migration increases in H2030 lung cancer cells on 
3D. 
H2030 spheroids were grown for four days and transferred to 2D plastic, and 3D 
IMR90 derived ECM. A) Images were captured at 0 and 48 hours after initial 
plating. B) Quantification of total migrated area relative to the area of the 
spheroid. Statistical analysis performed by unpaired T-test was performed, *** 
p<0.005; Data presented as mean ±S.E.M. 
22 
Because migration was increased on 3D, we wanted to investigate whether the 
type of matrix mattered. Hop62 spheroids were cultured on 2D, 3D IMR90 
derived matrix, and 3D CCL-201 (adult lung fibroblast) derived matrix for 48 
hours (Figure 3a). The migrational area of the spheroids was measured and 
quantified via ImageJ. Hop62 spheroid migration increased on 3D compared to 

















Figure 3. Collective cell migration of Hop62s increase on 3D regardless of 
the type of ECM used. 
Hop62 spheroids were grown for four days and transferred to 2D plastic and 
multiple 3D cell-derived ECM. B) Images were captured 48 hours after initial 
plating. A) Quantification of total migrated area relative to the area of the 
spheroid. Statistical analysis performed by 1-way ANOVA was performed with 
multiple comparisons; *** p<0.005; Data presented as mean ±S.E.M. 
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To investigate whether the phenotype was dependent on the migrational as 
performed, a scratch wound migration assay was performed with A549 NSCLC 
cells on 2D plastic and 3D IMR90 derived matrix (Figure 4a). The relative wound 
closures were recorded at 6, 24, and 48 hours and quantified via ImageJ. The 
wound closure was significantly increased on 3D compared to 2D at all time 
points (Figure 4b). These data suggest that NSCLC cells migrate more on 3D 
compared to 2D. 
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Figure 4. Relative wound closure is increased in A549 lung cancer cells on 
3D. 
A549 cancer cells are grown on 2D or 3D CDM at confluence, and a scratch 
wound is created. The excellent area is then either overlaid with complete media. 
A) Images were captured at 0, 6, 24, and 48 hours. B) Quantification of the
relative wound area. Statistical analysis performed by unpaired t-test was 
performed, ** p<0.01, *** p<0.005; Data presented as mean ±S.E.M. 
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Src inhibition blocks NSCLC migration. 
It had previously been shown that integrin signaling is altered in A549 cancer 
cells cultured on 2D compared to 3D cell-derived matrix [30]. It is well 
documented that Src plays a pivotal role in integrin signaling and cell migration 
[17, 34, 35]. To investigate the role of Src, an Src inhibitor (Saracatinib) was used 
to inhibit Src phosphorylation in Hop62, H2030, and A549 NSCLC cells. To 
determine the concertation of Saracatinib that was not lethal to Hop62 cells, an 
Alamar Blue cell viability assay with varying concentrations (0-20µM) of 
Saracatinib at 24, 48, and 72 hours was performed (Figure 5a). Next, Hop62 
cells were cultured on 2D and 3D with varying concentrations of Saracatinib (0-
10µM) to determine which concertation inhibits Src phosphorylation (Figure 5b). 
In Hop62 cells, saracatinib significantly inhibited Src phosphorylation at the 10µM 
range on 2D and the 5-10µM range on 3D (Figure 5b). 
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Figure 5. Saracatinib inhibits Src phosphorylation in Hop62 lung cancer 
cells. 
Hop62 cells were treated with varying concentrations of Saracatinib. A) Alamar 
Blue readings were recorded 24, 48, and 72 hours following treatment. B) Hop62 
cells were plated on 2D, and 3D IMR90 derived matrix. The cells were treated 
with varying concentrations of Saracatinib and collected 72 hours following 
treatment. Western blot analysis of the extracts was probed for p-src, src, and 
GAPDH. 
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To determine the concertation of Saracatinib that was not lethal to A549 cells, an 
Alamar Blue cell viability assay with varying concentrations (0-20µM) of 
Saracatinib at 24, 48, and 72 hours was performed (Figure 6a). Next, A549 cells 
were cultured on 2D and 3D with varying concentrations of Saracatinib (0-10µM) 
to determine which concertation inhibits Src phosphorylation (Figure 6b). 
Saracatinib significantly inhibited Src phosphorylation from the 0.6-10µM range in 
A549 cells on both 2D and 3D (Figure 6b). 
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Figure 6. Saracatinib inhibits Src phosphorylation in A549 lung cancer 
cells. 
A549 cells were treated with varying concentrations of Saracatinib. A) Alamar 
Blue readings were recorded 24, 48, and 72 hours following treatment. B) A549 
cells were plated on 2D, and 3D IMR90 derived matrix. The cells were treated 
with varying concentrations of Saracatinib and collected 72 hours following 
treatment. Western blot analysis of the extracts was probed for p-src, src, and 
GAPDH. 
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To determine the concertation of Saracatinib that was not lethal to H2030 cells, 
an Alamar Blue cell viability assay with varying concentrations (0-20µM) of 
Saracatinib at 24, 48, and 72 hours was performed (Figure 7a). Next, H2030 
cells were cultured on 2D and 3D with varying concentrations of Saracatinib (0-
10µM) to determine which concertation inhibits Src phosphorylation (Figure 7b). 
In H2030 cells, saracatinib significantly inhibited Src phosphorylation at the 1.25-
10µM range on 2D and the 2.5-10µM range on 3D (Figure 7b). 
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Figure 7. Saracatinib inhibits Src phosphorylation in H2030 lung cancer 
cells. 
H2030 cells were treated with varying concentrations of Saracatinib. A) Alamar 
Blue readings were recorded 24, 48, and 72 hours following treatment. B) H2030 
cells were plated on 2D, and 3D IMR90 derived matrix. The cells were treated 
with varying concentrations of Saracatinib and collected 72 hours following 
treatment. Western blot analysis of the extracts was probed for p-src, src, and 
GAPDH. 
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To assess the inhibition of Src's effect on cancer cell migration, spheroid assays 
were performed on 2D and 3D with multiple lung cancer cell lines and treated 
with Saracatinib or not. Hop62 cell spheroids, treated with 5µM of Saracatinib or 
a DMSO vehicle control, were cultured on 2D plastic and 3D IMR90-derived 
matrix for 48 hours (Figure 8a). The migrational area of the spheroids was 
measured and quantified via ImageJ. Hop62 spheroids treated with Saracatinib 
migrated significantly less on 2D and 3D compared to the vehicle control (Figure 
8b). 
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Figure 8. Saracatinib blocks the collective migration of Hop62 lung cancer 
cells. 
Hop62 spheroids were grown for four days and transferred to 2D plastic, and 3D 
IMR90 derived ECM. The spheroids were treated with Saracatinib (5µM) or 
Vehicle (DMSO). A) Images were captured 48 hours after initial plating. B) 
Quantification of total migrated area relative to the area of the spheroid. 
Statistical analysis performed by 2-way ANOVA was performed with multiple 
comparisons, *** p<0.005, **** p<0.001; Data presented as mean ±S.E.M. 
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A549 cell spheroids, treated with 5µM of Saracatinib or a DMSO vehicle control, 
were cultured on 2D plastic and 3D IMR90-derived matrix for 48 hours (Figure 
9a). The migrational area of the spheroids was measured and quantified via 
ImageJ. A549 spheroids treated with Saracatinib migrated significantly less on 
2D and 3D compared to the vehicle control (Figure 9b). 
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Figure 9. Saracatinib blocks the collective migration of A549 lung cancer 
cells.   
A549 spheroids were grown for four days and transferred to 2D plastic, and 3D 
IMR90 derived ECM. The spheroids were treated with Saracatinib (5µM) or 
Vehicle (DMSO). A) Images were captured 48 hours after initial plating. B) 
Quantification of total migrated area relative to the area of the spheroid. 
Statistical analysis performed by 2-way ANOVA was performed with multiple 
comparisons, **** p<0.001; Data presented as mean ±S.E.M. 
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H2030 cell spheroids, treated with 5µM of Saracatinib or a DMSO vehicle control, 
were cultured on 2D plastic and 3D IMR90-derived matrix for 48 hours (Figure 
8a). The migrational area of the spheroids was measured and quantified via 
ImageJ. H2030 spheroids treated with Saracatinib migrated significantly less on 
2D and 3D compared to the vehicle control (Figure 10b). 
These data support that inhibiting Src phosphorylation blocks migration of 
NSCLC cell spheroids regardless of being cultured on 2D plastic or 3D cell-
derived matrix. 
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Figure 10. Saracatinib blocks the collective migration of H2030 lung cancer 
cells.  
H2030 spheroids were grown for four days and transferred to 2D plastic, and 3D 
IMR90 derived ECM. The spheroids were treated with Saracatinib (5µM) or 
Vehicle (DMSO). A) Images were captured 48 hours after initial plating. B) 
Quantification of total migrated area relative to the area of the spheroid. 
Statistical analysis performed by 2-way ANOVA was performed with multiple 
comparisons, ** p<0.01, **** p<0.001; Data presented as mean ±S.E.M.  
38 
FAK inhibition alters NSCLC cell migration on 2D and 3D. 
FAK phosphorylation is an essential downstream signal for integrin activation. To 
further investigate how FAK phosphorylation plays a role in cancer cell migration, 
we treated Hop62, A549, and H2030 lung cancer cells with PF-573228 (Cayman 
#S2013), a FAK397 autophosphorylation inhibitor. 
To determine the concertation of PF-573228 that did not kill Hop62 cells, an 
Alamar Blue cell viability assay with varying concentrations (0-20µM) of PF-
573228 at 24, 48, and 72 hours was performed (Figure 11a). Next, Hop62 cells 
were cultured on 2D and 3D with varying concentrations of PF-573228 (0-5µM) 
to determine which concertation inhibits FAK397 phosphorylation (Figure 11b). In 
Hop62 cells, PF-573228 significantly inhibited FAK397 phosphorylation at the 2.5-
5µM range on 2D plastic and 5µM on 3D CDM. 
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Figure 11. PF-573228 inhibits the autophosphorylation of FAK in Hop62 
lung cancer cells. 
Hop62 cells were treated with varying concentrations of the FAK inhibitor, PF-
573228. A) Alamar Blue readings were recorded 24, 48, and 72 hours following 
treatment. B) Hop62 cells were plated on 2D, and 3D IMR90 derived matrix. The 
cells were treated with varying concentrations of Saracatinib and collected 72 
hours following treatment. Western blot analysis of the extracts was probed for p-
FAK, FAK, and GAPDH. 
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To determine the concertation of PF-573228 that did not kill A549 cells, an 
Alamar Blue cell viability assay with varying concentrations (0-20µM) of PF-
573228 at 24, 48, and 72 hours was performed (Figure 12a). Next, A549 cells 
were cultured on 2D and 3D with varying concentrations of PF-573228 (0-10µM) 
to determine which concertation inhibits FAK397 phosphorylation (Figure 11b). In 
Hop62 cells, PF-573228 significantly inhibited FAK397 phosphorylation at the 5-
10µM range on 2D and 3D (Figure12b). 
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Figure 12. PF-573228 inhibits the autophosphorylation of FAK in A549 lung 
cancer cells.  
A549 cells were treated with varying concentrations of the FAK inhibitor, PF-
573228. A) Alamar Blue readings were recorded 24, 48, and 72 hours following 
treatment. B) A549 cells were plated on 2D, and 3D IMR90 derived matrix. The 
cells were treated with varying concentrations of Saracatinib and collected 72 
hours following treatment. Western blot analysis of the extracts was probed for p-
FAK, FAK, and GAPDH. 
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To assess the inhibition of FAK's effect on cancer cell migration, spheroid assays 
were performed on 2D and 3D with multiple lung cancer cell lines and treated 
with PF-573228 or not. Hop62 cell spheroids, treated with 5µM of PF-573228 or 
a DMSO vehicle control, were cultured on 2D plastic and 3D IMR90-derived 
matrix for 48 hours (Figure 13a). The migrational area of the spheroids was 
measured and quantified via ImageJ. Hop62 spheroids treated with PF-573228 
migrated significantly less on 3D but not 2D compared to the vehicle control 
(Figure 13b). 
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Figure 13. PF-573228 decreases the collective cell migration of Hop62 lung 
cancer cells.  
Hop62 spheroids were grown for four days and transferred to 2D plastic, and 3D 
IMR90 derived ECM. The spheroids were treated with PF-573228 (5µM) or 
Vehicle (DMSO). A) Images were captured 48 hours after initial plating. B) 
Quantification of total migrated area relative to the area of the spheroid. 
Statistical analysis performed by 2-way ANOVA was performed with multiple 
comparisons, * p<0.05, ** p<0.01; Data presented as mean ±S.E.M. 
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A549 cell spheroids, treated with 5µM of PF-573228 or a DMSO vehicle control, 
were cultured on 2D plastic and 3D IMR90-derived matrix for 48 hours (Figure 
14a). The migrational area of the spheroid was measured and quantified via 
ImageJ. There was no statistically significant difference in the migration of A549 
spheroids treated with PF-573228 on 2D or 3D (Figure 14b). 
These results suggest inhibition of FAK397 phosphorylation's influence on cell 
migration is cell condition (2Dv3D) and cell line (Hop62vA549vH2030) 
dependent. 
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Figure 14. PF-573228 does not impact the collective cell migration of A549 
lung cancer cells. 
A549 spheroids were grown for four days and transferred to 2D plastic, and 3D 
IMR90 derived ECM. The spheroids were treated with PF-573228 (5µM) or 
Vehicle (DMSO). A) Images were captured 48 hours after initial plating. B) 
Quantification of total migrated area relative to the area of the spheroid. 
Statistical analysis performed by 2-way ANOVA was performed with multiple 
comparisons; Data presented as mean ±S.E.M. 
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Co-cultured fibroblast migration is Src-independent on 3D. 
The tumor microenvironment is composed of many different cell types. Of those 
cell types, fibroblasts are the most important for ECM production and 
degradation. To investigate how fibroblasts play a role in cancer cell migration, 
spheroid assays were performed, culturing both cancer cells and fibroblasts 
together. In a 1:5 Hop62: IMR90GFP ratio, co-cultured spheroids were created, 
transferred to 2D and 3D, and cultured for 72 hours (Figure 15a). Light and 
fluorescence microscopy photos were captured, then measured and quantified 
using ImageJ. The cancer cells were not fluorescently labeled, but the fibroblasts 
were, allowing for separate quantification between the cancer cell and fibroblast 
migration. The area cancer cell migration was not significantly changed on 2D or 
3D, but the area of fibroblast migration was significantly increased on 3D 
compared to 2D (Figure 15b). 
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Figure 15. IMR90 lung fibroblasts co-cultured with A549 lung cancer cells 
migrate more on 3D CDM.  
Co-cultured spheroids consisting of A549 and GFP labeled IMR90 lung 
fibroblasts in a 1:5 ratio, respectively, were grown for 4 days and transferred to 
2D plastic or 3D IMR90 derived ECM. A) Pictures were taken 72 hours following 
transfer (bright field on the left, fluorescence on the right). B) Quantification of 
total migrated area relative to the area of spheroid Statistical analysis performed 
by 2-way ANOVA was performed with multiple comparisons, ** p<0.01, **** 
p<0.001; Data presented as mean ±S.E.M. 
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We previously showed that treatment of an Src inhibitor, Saracatinib, significantly 
reduced the migration of Hop62, A549, and H2030 cells on 2D and 3D. Because 
we saw such a noticeable migrational and phenotypic difference in the migration 
of co-cultured fibroblasts on 2D compared to 3D, we wanted to investigate the 
impact of Src inhibition on our co-cultured system. First, we needed to determine 
the concertation of Saracatinib that was not lethal to IMR90 cells. To do this, an 
Alamar Blue cell viability assay with varying concentrations (0-20µM) of 
Saracatinib at 24, 48, and 72 hours was performed (Figure 16a). Next, IMR90 
cells were cultured on 2D and 3D with varying concentrations of Saracatinib (0-
10µM) to determine which concertation inhibits Src phosphorylation (Figure 23b). 
Saracatinib significantly inhibited Src phosphorylation from the 0.6-10µM range in 
IMR90 cells on both 2D and 3D (Figure 16b). 
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Figure 16. Saracatinib inhibits Src phosphorylation in IMR90 lung 
fibroblasts.  
IMR90 lung fibroblasts were treated with varying concentrations of Saracatinib. 
A) Alamar Blue readings were recorded 24, 48, and 72 hours following treatment.
B) IMR90 lung fibroblasts were plated on 2D, and 3D IMR90 derived matrix. The
cells were treated with varying concentrations of Saracatinib and collected 72 
hours following treatment. Western blot analysis of the extracts was probed for p-
src, src, and GAPDH. 
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To investigate how Src inhibition impacted the cancer cell and fibroblast 
migration, a spheroid co-culture assay was performed. In a 1:5 A549: IMR90GFP 
ratio, co-cultured spheroids, treated with 5µM of Saracatinib or DMSO vehicle, 
were cultured on 2D and 3D for 72 hours (Figure 17a). Light and fluorescence 
microscopy photos were captured, then measured and quantified using ImageJ. 
The cancer cells were not fluorescently labeled, but the fibroblasts were, allowing 
for separate quantification between the cancer cell and fibroblast migration 
(Figure 17b). When treated with saracatinib, cancer cell and fibroblast migration 
decreased on 2D and 3D. Untreated spheroid cancer cell migration did not differ 
on 2D and 3D. However, fibroblast migration significantly increased on 3D 
compared to 2D. This data suggests fibroblasts migrate more on 3D and in an 
Src-dependent manner on 2D, but not 3D, when co-cultured with A549 cancer 
cells. 
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Figure 17. Saracatinib blocks the migration of IMR90 lung fibroblasts co-
cultured with A549 lung cancer cells on 2D but not 3D.  
Co-cultured spheroids consisting of A549 and IMR90 lung fibroblasts in a 1:5 
ratio, respectively, were grown for 4 days and transferred to 2D plastic or 3D 
IMR90 derived ECM. The spheroids were treated with Saracatinib (5µM) or 
Vehicle (DMSO). A) Pictures were taken 72 hours following transfer (bright field 
on the left, fluorescence on the right). B) Quantification of total migrated area 
relative to the area of the spheroid. Statistical analysis performed by 2-way 
ANOVA was performed with multiple comparisons, ** p<0.01, **** p<0.001; Data 
presented as mean ±S.E.M. 
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In a 1:5 Hop62: IMR90GFP ratio, co-cultured spheroids, treated with 5µM of 
Saracatinib, or DMSO vehicle, was cultured on 2D and 3D for 72 hours (Figure 
18a). Light and fluorescence microscopy photos were captured, then measured 
and quantified using ImageJ. The cancer cells were not fluorescently labeled, but 
the fibroblasts were, allowing for separate quantification between the cancer cell 
and fibroblast migration (Figure 18b). When treated with saracatinib, cancer cell 
migration was significantly decreased on 2D and appeared to decrease on 3D. 
However, fibroblast migration significantly decreased on 3D but not 2D. 
Untreated spheroid cancer cell migration did not differ on 2D and 3D. However, 
fibroblast migration significantly increased on 3D compared to 2D. This data 
suggests fibroblasts migrate more on 3D and in an Src-dependent manner on 2D 
when co-cultured with Hop62 cancer cells. 
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Figure 18. Saracatinib blocks the migration of IMR90 lung fibroblasts co-
cultured with Hop62 lung cancer cells on 2D but not 3D.  
Co-cultured spheroids consisting of Hop62 and IMR90 lung fibroblasts in a 1:5 
ration, respectively, were grown for 4 days and transferred to 2D plastic or 3D 
IMR90 derived ECM. The spheroids were treated with Saracatinib (5µM) or 
Vehicle (DMSO). A) Pictures were taken 72 hours following transfer (bright field 
on the left, fluorescence on the right). B) Quantification of total migrated area 
relative to the area of the spheroid. Statistical analysis performed by 2-way 
ANOVA was performed with multiple comparisons, ** p<0.01, **** p<0.001; Data 
presented as mean ±S.E.M. 
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To investigate fibroblast migration independently of cancer cells on 2D, IMR90 
fibroblasts were cultured at a low density on 2D and treated with Saracatinib or 
not (Figure 19a and b). Treatment with Saracatinib significantly decreased 
fibroblast displacement, acceleration, and speed on 2D (Figure 19c). 
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Figure 19. Saracatinib impacts the single cell migration of IMR90 lung 
fibroblasts on 2D.  
IMR90 cells were plated at a low concentration on 2D plastic. Time-lapse 
imaging was recorded, imaging every 15 minutes for 24 hours. IMR90s were 
treated with either A) Vehicle (DMSO) or B) Saracatinib (5µM) C) Single-cell 
speed, distance, and acceleration were recorded. Statistical analysis performed 
by 2-way ANOVA was performed with multiple comparisons. Statistical analysis 
performed by 2-way ANOVA was performed with multiple comparisons, * 
p<0.05** p<0.01, **** p<0.001; Data presented as mean ±S.E.M. 
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To investigate fibroblast migration independently of cancer cells on 3D, IMR90 
fibroblasts were cultured at a low density on 3D and treated with Saracatinib or 
not (Figure 20a and b). Treatment with Saracatinib did not significantly decrease 
fibroblast displacement, acceleration, or speed on 3D (Figure 20c). 
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Figure 20. Saracatinib does not impact the single cell migration of IMR90 
lung fibroblasts on 3D. 
 IMR90 cells were plated at a low concentration on 3D IMR90 derived ECM. 
Time-lapse imaging was recorded, imaging every 15 minutes for 24 hours. 
IMR90s were treated with either A) Vehicle (DMSO) or B) Saracatinib (5µM) C) 
Single-cell speed, distance, and acceleration were recorded. Statistical analysis 
performed by 2-way ANOVA was performed with multiple comparisons. 
58 
DISCUSSION 
In this study, we investigated the role of integrin signaling, specifically Src, 
in the context of NSCLC cell and fetal lung fibroblast migration on fetal lung 
fibroblast-derived extracellular matrix. Our lab has previously demonstrated that 
lung cancer cells alter their migration and integrin signaling on 3D cell-derived 
matrix compared to 2D plastic [30]. Historically, cancer cell migration has been 
studied in vitro utilizing plastic dishes. Here, we use a system using cell-derived 
matric as a more physiologically relevant cell culture method and study the 
interaction between cancer cells and the extracellular matrix (ECM). Fibroblasts 
are the primary ECM producers and remodelers. This study highlighted the 
differential cancer cell and fibroblast migration on 2D and 3D while perturbing 
integrin signaling. 
Schertzer et al. demonstrated that the single cell migration of cancer cells 
is differentially altered on 2D and 3D. Furthermore, Src and FAK phosphorylation 
was increased in NSCLC cells cultured on 3D. To further investigate this 
phenotype, we developed a collective cell spheroid migration assay on 2D plastic 
and 3D CDM. In multiple cell lines, collective cell migration was increased on 3D 
CDM (Figures 1 and 2), suggesting that the ECM influenced cancer cell 
migration. To increase scientific rigor, a scratch wound assay on 2D and 3D 
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CDM was performed using A549 NSCLC cells (Figure 3), where collective cell 
migration increased on 3D CDM. This data suggested that culturing NSCLC cells 
on 3D CDM influenced collective cancer cell migration. 
As previously stated, our group has shown that Src and FAK signaling is 
increased in NSCLC cells cultured on 3D CDM. Src and FAK's role in cell 
adhesion and migration is well documented [17]. Saracatinib is a well-
documented Src inhibitor [36], as well as a known inhibitor of EGFR and Abl, and 
has been tested in multiple clinical trials but failed due to lack and efficacy and 
harsh side effects. Regardless of the failed trials, Saracatinib is a potent Src 
inhibitor. To investigate how inhibiting Src impacts NSCLC collective cell 
migration, spheroid assays were performed with multiple NSCLC cell lines on 2D 
and 3D treating with 5µM Saracatinib or DMSO vehicle (Figures 8-10). Inhibition 
of Src completely blocked collective cell migration regardless of cell culture 
conditions or cell line. PF-573228 inhibits the phosphorylation of FAK at its 397 
autophosphorylation site. To investigate how inhibiting FAK397 phosphorylation 
impacts NSCLC collective cell migration, spheroid assays were performed with 
Hop62 and A549 NSCLC cell lines on 2D and 3D, and treated with 5µM PF-
573228 or DMSO vehicle (Figures 8-9). Interestingly enough, Hop62 collective 
cell migration was decreased by PF-573228 on 3D, but not 2D. However, A549 
collective cell migration was not affected by PF-573228 treatment regardless of 
the condition. This data suggested that Src plays a more critical role in cancer 
cell migration than FAK. 
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Fibroblasts are among the most abundant cell types in the tumor 
microenvironment and are responsible for remodeling and producing ECM. We 
developed a system to co-culture cancer cells and fibroblasts together to create 
co-cultured spheroids. When monitoring collective cell migration of A549-IMR90 
co-cultured spheroids, IMR90 fibroblast migration was significantly increased on 
3D compared to 2D. This data suggests that when IMR90 cells interact with the 
cell-derived ECM, migrational phenotypes are enhanced. Because inhibiting Src 
completely blocked the collective cell migration of cancer cells, we wanted to 
investigate co-cultured spheroid migration when Src is inhibited with Saracatinib. 
Interestingly enough, Saracatinib decreased cancer cell migration regardless of 
conditions, where fibroblast migration was also decreased, but not to the same 
extent. Compared to the cancer cells, the fibroblasts migrated significantly more 
even when treated with Saracatinib. This data suggested that fibroblasts 
migrated in a more Src-independent manner than cancer cells on 3D CDM. 
Because we saw a difference in the cancer cell and fibroblast migration 
when treated with Saracatinib, we investigated the migration of fibroblasts on 2D 
and 3D, treated with Saracatinib or DMSO vehicle, independently of cancer cells 
via single cell tracking. When treated with Saracatinib, fibroblast speed, 
acceleration, and distance were significantly different between the vehicle-treated 
group on 2D, but there was no difference between groups on 3D. This result 
further supported our hypothesis that fibroblasts migrated in an Src-independent 
manner on 3D CDM. 
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It is well understood that fibroblasts play a critical role in facilitating cancer 
cell metastasis [37]. This study is crucial in understanding how fibroblasts 
migrate in the presence of cancer cells and not. Our results suggest that cancer 
cells cultured on 3D cell-derived matrix migrate in a Src-dependent manner while 
fibroblasts do not. These findings are important because they may explain why 
Src inhibitors, such as Saracatinib, may have failed clinical trials due to 
effectiveness. It is also important to note that we see the differences in modes of 
migration of fibroblasts on 2D compared to 3D cell-derived matrix, a model 
proposed to be more physiologically relevant. Understanding the mechanisms of 
migration of cancer cells and fibroblasts when interacting with the ECM may be 
crucial in targeting cancer metastasis. 
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SUMMARY 
Lung cancer is the most lethal type of cancer in males and females 
primarily due to its metastatic spread. There has yet to be FDA-approved 
treatment to treat lung cancer metastasis. To approach this knowledge gap, we 
investigated the interactions between multiple components of the tumor 
microenvironment. To this extent, we established a cell culture system that 
mimics physiological conditions. Briefly, fibroblasts are cultured at confluence, 
decellularized on the dish, and what's left behind is a 3D fibroblast-deposited 
matrix. Utilizing this system allows us to study the interaction between NSCLC 
cells and fibroblast-derived ECM. 
When NSCLC cells are cultured on a fibroblast-derived matrix, their 
velocity, directionality, and displacement increase. To investigate cancer cell 
migration, we performed spheroid and scratch wound assays. Our results 
revealed that cancer cell migration increased on 3D in multiple cell lines and 
multiple migration assays. Because SRC signaling increased in cancer cells 
cultured on 3D, we pharmacologically inhibited SRC in our spheroid assay. 
Inhibiting SRC significantly decreased migration regardless of culture conditions. 
To further investigate how fibroblasts impact cancer cell migration, co-cultured 
spheroid assays were performed. Fibroblast migration increased on 3D, but 
cancer cell migration did not. We treated the co-cultured spheroids with an SRC 
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inhibitor. To our surprise, fibroblast migration decreased on 2D but not 3D. These 
studies demonstrate that cancer cells and fibroblasts migrated through different 
mechanisms on 3D fibroblast-derived matrix. Future studies will investigate the 
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